Evidence map›Paper›PMID 40899264›Full record

ArticleDisease models & mechanisms2025

Immunological dynamics in orthotopic compared with subcutaneous murine models of HPV-positive oropharyngeal cancer.

Minzi Mao, Ke Qiu, Lan Feng, Yao Song, Yufang Rao, Shuo Li, Danni Cheng, Xiuli Shao, Chuanhuan Jiang, Shenglan You and 8 more

Abstract readComparative Study
In one paragraph

Article in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Minzi MaoDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.ORCID 0000-0002-8777-6770
Ke QiuDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Lan FengDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Yao SongDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Yufang RaoDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Shuo LiDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Danni ChengDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Xiuli ShaoDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Chuanhuan JiangDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Shenglan YouAnimal Imaging Core Facilities, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Wei XuDepartment of Biostatistics, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, M5G 2C1 Toronto, Ontario, Canada.
Geoffrey LiuDepartment of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, M5G 2C1 Toronto, Canada.
Jadwiga JablonskaTranslational Oncology, Department of Otolaryngology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Stephan LangTranslational Oncology, Department of Otolaryngology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Shuaicheng LiDepartment of Computer Science, City University of Hong Kong, 999077 Hong Kong, China.
Fei ChenDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Yu ZhaoDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
Jianjun RenDepartment of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.ORCID 0000-0002-5938-688X

Funding

Chengdu Science and Technology Bureau 2024-YF05-00908-SNCoreNational Natural Science Foundation of China 2023HXBH121National Natural Science Foundation of China 2024HXBH111National Natural Science Foundation of China 2024NSFSC1510National Natural Science Foundation of China 2024NSFSC1513National Natural Science Foundation of China 2024-YF05-00908-SNNational Natural Science Foundation of China 2025ZNSFSC1528National Natural Science Foundation of China 2025ZNSFSC1530National Natural Science Foundation of China 82403589Science and Technology Department of Sichuan Province 2024NSFSC1510Science and Technology Department of Sichuan Province 2024NSFSC1513Science and Technology Department of Sichuan Province 2024YFHZ0335Science and Technology Department of Sichuan Province 2025ZNSFSC1528Science and Technology Department of Sichuan Province 2025ZNSFSC1530Sichuan UniversitySichuan University Interdisciplinary Innovation Fundthe National Natural Science Foundation of China 82272777;82471153the National Natural Science Foundation of China 82403589West China Hospital of Sichuan UniversityWest China Hospital, Sichuan University 2023HXBH121West China Hospital, Sichuan University 2024HXBH111
6 · The paper itself

Abstract

The necessity of reliable preclinical models for evaluating the efficacy of novel therapeutic strategies is imperative. Nevertheless, the degree to which tumor-bearing murine models represent the immunological characteristics of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) has largely been unexplored. By utilizing single-cell RNA sequencing technology, our research elucidated that subcutaneous (SC) murine models more accurately reflect the early immunogenic phase of human HPV-positive OPSCC, marked by a stage-dependent increase in effector T-cell infiltration. By contrast, orthotopic (base of tongue, BOT) tumors exhibited a progressive decline of cytotoxic T cells and accumulation of myeloid-derived suppressive cells, paralleling the immune decrease observed in advanced, immune-excluded human tumors. Additionally, our drug responsiveness analysis indicated that early-stage BOT models more accurately replicate the response to PDCD1 blockade, whereas late-stage SC models more accurately mirror the response to CTLA4 blockade akin to human samples. Our findings provide pivotal insights into the suitability of murine models for the preclinical assessment of immunotherapies in HPV-positive OPSCC.

Indexed as

Oropharyngeal NeoplasmsPapillomaviridaePapillomavirus InfectionsSubcutaneous TissueAnimalsDisease Models, AnimalFemaleHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLMyeloid-Derived Suppressor CellsProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 ReceptorDrug sensitivityHuman papillomavirus (HPV)-positive head and neck squamous cell carcinoma (OPSCC)Murine modelsTumor immune microenvironment (TIME)

Identifiers

PMID40899264
PMCPMC12746710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.